A. Kuendgen

1.5k total citations
22 papers, 690 citations indexed

About

A. Kuendgen is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, A. Kuendgen has authored 22 papers receiving a total of 690 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 10 papers in Molecular Biology and 10 papers in Genetics. Recurrent topics in A. Kuendgen's work include Acute Myeloid Leukemia Research (19 papers), Histone Deacetylase Inhibitors Research (9 papers) and Chronic Lymphocytic Leukemia Research (4 papers). A. Kuendgen is often cited by papers focused on Acute Myeloid Leukemia Research (19 papers), Histone Deacetylase Inhibitors Research (9 papers) and Chronic Lymphocytic Leukemia Research (4 papers). A. Kuendgen collaborates with scholars based in Germany, Italy and United States. A. Kuendgen's co-authors include Michael Lübbert, Corinna Strupp, Ulrich Germing, Matteo Giovanni Della Porta, Luca Malcovati, Ilaria Ambaglio, Ulrich Germing, E. Zipperer, Kathrin Nachtkamp and Norbert Gattermann and has published in prestigious journals such as Blood, Cancer Treatment Reviews and Haematologica.

In The Last Decade

A. Kuendgen

21 papers receiving 679 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Kuendgen Germany 10 572 296 232 90 65 22 690
Ilaria Ambaglio Italy 8 750 1.3× 507 1.7× 164 0.7× 90 1.0× 71 1.1× 15 798
Kathrin Nachtkamp Germany 15 808 1.4× 427 1.4× 184 0.8× 148 1.6× 86 1.3× 53 876
Arjan van de Loosdrecht Netherlands 9 547 1.0× 252 0.9× 123 0.5× 60 0.7× 108 1.7× 22 643
Hege Garelius Sweden 11 494 0.9× 196 0.7× 159 0.7× 120 1.3× 36 0.6× 29 557
O. Krieger Austria 13 375 0.7× 253 0.9× 123 0.5× 85 0.9× 66 1.0× 41 600
Tiejun Qin China 15 471 0.8× 323 1.1× 232 1.0× 42 0.5× 39 0.6× 88 599
J O Moore United States 9 436 0.8× 126 0.4× 148 0.6× 169 1.9× 36 0.6× 9 600
Christiane Schumann Germany 8 476 0.8× 256 0.9× 214 0.9× 82 0.9× 21 0.3× 11 590
Mónica Cabrero Spain 11 382 0.7× 106 0.4× 145 0.6× 48 0.5× 21 0.3× 33 558
Franca Radaelli Italy 13 746 1.3× 730 2.5× 282 1.2× 86 1.0× 17 0.3× 23 961

Countries citing papers authored by A. Kuendgen

Since Specialization
Citations

This map shows the geographic impact of A. Kuendgen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Kuendgen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Kuendgen more than expected).

Fields of papers citing papers by A. Kuendgen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Kuendgen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Kuendgen. The network helps show where A. Kuendgen may publish in the future.

Co-authorship network of co-authors of A. Kuendgen

This figure shows the co-authorship network connecting the top 25 collaborators of A. Kuendgen. A scholar is included among the top collaborators of A. Kuendgen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Kuendgen. A. Kuendgen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kuendgen, A., Catharina Müller‐Thomas, Michael Lauseker, et al.. (2013). Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine. Blood. 122(21). 2757–2757. 2 indexed citations
3.
Such, Esperanza, Ulrich Germing, Luca Malcovati, et al.. (2013). Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 121(15). 3005–3015. 179 indexed citations
4.
Schroeder, Thomas, A. Kuendgen, Sabine Käyser, et al.. (2011). Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica. 97(2). 206–212. 25 indexed citations
5.
Kuendgen, A., Thomas Schroeder, Ariane Dienst, et al.. (2011). 93 Analysis of treatment choices and outcome for MDS and AML patients 60 years and older from the university of Dusseldorf. Leukemia Research. 35. S35–S35. 1 indexed citations
6.
Kuendgen, A., Gesine Bug, Oliver G. Ottmann, et al.. (2011). Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Clinical Epigenetics. 2(2). 389–399. 29 indexed citations
7.
Neukirchen, Judith, Barbara Hildebrandt, A. Kuendgen, et al.. (2011). 312 Restratification of IPSS risk groups according to the WPSS identifies patients with myelodysplastic syndromes (MDS) at higher risk. Leukemia Research. 35. S124–S124. 1 indexed citations
8.
Porta, Matteo Giovanni Della, Luca Malcovati, Corinna Strupp, et al.. (2010). Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 96(3). 441–449. 164 indexed citations
9.
Zipperer, E., Kathrin Nachtkamp, A. Kuendgen, et al.. (2009). The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica. 94(5). 729–732. 64 indexed citations
10.
Giagounidis, Aristoteles, Gudrun Göhring, Sabine Haase, et al.. (2009). Discontinuation of Lenalidomide in Patients with Transfusion-Dependent Low- and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5q): Sustained Remissions, but Not Cure.. Blood. 114(22). 3807–3807. 1 indexed citations
11.
Kuendgen, A. & Michael Lübbert. (2008). Current status of epigenetic treatment in myelodysplastic syndromes. Annals of Hematology. 87(8). 601–611. 71 indexed citations
12.
Kuendgen, A. & Ulrich Germing. (2008). Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly. Cancer Treatment Reviews. 35(2). 97–120. 45 indexed citations
13.
Kuendgen, A., Gesine Bug, Oliver G. Ottmann, et al.. (2008). Treatment of Poor Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia with a Combination of 5-Azacytidine and Valproic Acid. Blood. 112(11). 3639–3639. 8 indexed citations
14.
Zohren, Fabian, Corinna Strupp, A. Kuendgen, et al.. (2008). Characteristics of Disease Progression in 3213 Patients with Myelodysplastic Syndrome. Blood. 112(11). 2689–2689. 2 indexed citations
15.
Germing, Ulrich, Corinna Strupp, A. Kuendgen, et al.. (2007). Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica. 92(7). 974–977. 44 indexed citations
16.
Kuendgen, A., Thorsten Gräf, Fabian Zohren, et al.. (2006). Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine. Leukemia Research. 31(3). 407–409. 9 indexed citations
17.
Kuendgen, A., Barbara Hildebrandt, Floyd E. Fox, et al.. (2005). P-112 Results of a phase II trial with valproic acid (VPA) alone or in combination with all-trans-retinoic acid (ATRA) in 71 patients with myelodysplastic syndromes or SAML/MDS. Leukemia Research. 29. S66–S66. 1 indexed citations
18.
Haase, Dagmar, Christian Steidl, Julie Schanz, et al.. (2005). Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS.. Blood. 106(11). 787–787. 10 indexed citations
19.
Malcovati, Luca, Ulrich Germing, A. Kuendgen, et al.. (2005). A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.. Blood. 106(11). 788–788. 21 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ilaria Ambaglio Breakdown of academic impact, for papers by Kathrin Nachtkamp Breakdown of academic impact, for papers by Arjan van de Loosdrecht Breakdown of academic impact, for papers by Hege Garelius Breakdown of academic impact, for papers by O. Krieger Breakdown of academic impact, for papers by Tiejun Qin Breakdown of academic impact, for papers by J O Moore Breakdown of academic impact, for papers by Christiane Schumann Breakdown of academic impact, for papers by Mónica Cabrero Breakdown of academic impact, for papers by Franca Radaelli
Rankless by CCL
2026